ILMN vs. WAT, BRKR, BIO, AVTR, RVTY, BIO.B, LH, HOLX, BAX, and BGNE
Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Waters (WAT), Bruker (BRKR), Bio-Rad Laboratories (BIO), Avantor (AVTR), Revvity (RVTY), Bio-Rad Laboratories (BIO.B), Laboratory Co. of America (LH), Hologic (HOLX), Baxter International (BAX), and BeiGene (BGNE).
Waters (NYSE:WAT) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Waters has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500.
94.0% of Waters shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 0.8% of Waters shares are owned by insiders. Comparatively, 0.2% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Waters has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.
In the previous week, Waters had 38 more articles in the media than Illumina. MarketBeat recorded 49 mentions for Waters and 11 mentions for Illumina. Waters' average media sentiment score of 0.77 beat Illumina's score of 0.14 indicating that Illumina is being referred to more favorably in the news media.
Illumina received 650 more outperform votes than Waters when rated by MarketBeat users. Likewise, 65.71% of users gave Illumina an outperform vote while only 54.30% of users gave Waters an outperform vote.
Waters has a net margin of 20.75% compared to Waters' net margin of -28.71%. Illumina's return on equity of 66.59% beat Waters' return on equity.
Waters currently has a consensus target price of $305.78, indicating a potential downside of 8.65%. Illumina has a consensus target price of $164.65, indicating a potential upside of 56.85%. Given Waters' stronger consensus rating and higher probable upside, analysts plainly believe Illumina is more favorable than Waters.
Summary
Waters beats Illumina on 10 of the 18 factors compared between the two stocks.
Get Illumina News Delivered to You Automatically
Sign up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Illumina Competitors List
Related Companies and Tools
